Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) Platform
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...
NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies,...